EMA Recommends Five Medicines for Approval
In terms of extensions, the committee recommended Adcirca, Dupixent, Edistride, Enhertu, Fintepla, Forxiga, Hemlibra, Imfinzi (including two new indications), Kerendia, Spikevax and Triumeq.
The European Medicines Agency’s (EMA’s) human medicines committee (CHMP) recommended five medicines for approval at the committee’s December 2022 meeting.
The recommended medicines include:
- Hemgenix (etranacogene dezaparvovec) as an advanced therapy medicinal product and as the first gene therapy for the treatment of severe and moderately severe Hemophilia B
- Imjudo (tremelimumab) to be used in combination with Imfinzi (durvalumab) for the treatment of adults with hepatocellular carcinoma
- Tremelimumab AstraZeneca (tremelimumab) for the treatment of metastatic non-small lung cancer in combination with Imfinzi and platinum-based chemotherapy
- Pombiliti for the treatment of glycogen storage disease type 2, or Pompe disease
- Dimethyl fumarate Accord (dimethyl fumarate) for the treatment of multiple sclerosis.
With these positive reviews, the CHMP also recommended the refusal of a marketing authorization for Omblastys for the treatment of neuroblastoma, which is a rare type of cancer.
In terms of extensions, the committee recommended Adcirca, Dupixent, Edistride, Enhertu, Fintepla, Forxiga, Hemlibra, Imfinzi (including two new indications), Kerendia, Spikevax and Triumeq.
Source: European Medicines Agency
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
